BCR and chronic myelogenous leukemia, BCR-ABL1 positive: This initialized with the discovery of a small-molecule kinase inhibitor specifically targeted to the mutant BCR-ABL protein present in the tumor cells of patients with chronic myeloid leukemia (CML).